[HTML][HTML] A comparative study on erlotinib & gefitinib therapy in non-small cell lung carcinoma patients
P Thomas, B Vincent, C George… - Indian Journal of …, 2019 - journals.lww.com
… study showed that erlotinib and gefitinib had similar effectiveness but gefitinib had a better
safety profile compared to erlotinib… for NSCLC patients compared to erlotinib. However, further …
safety profile compared to erlotinib… for NSCLC patients compared to erlotinib. However, further …
[HTML][HTML] Comparing efficacy of erlotinib and bevacizumab combination with erlotinib monotherapy in patients with advanced non-small cell lung cancer (NSCLC): A …
P Sakharkar, S Kurup - Diseases, 2023 - mdpi.com
… Nine studies comprising 1698 patients with NSCLC were included in this meta-analysis, of
whom 850 were treated with erlotinib plus bevacizumab, and 848 with erlotinib. The erlotinib …
whom 850 were treated with erlotinib plus bevacizumab, and 848 with erlotinib. The erlotinib …
[HTML][HTML] Erlotinib-loaded dendrimer nanocomposites as a targeted lung cancer chemotherapy
… Comparative in situ study showed that cationic G4 erlotinib-… to neutral G5 erlotinib-loaded
dendrimers and erlotinib alone. These … The aim of this work is to design non-invasive erlotinib …
dendrimers and erlotinib alone. These … The aim of this work is to design non-invasive erlotinib …
[HTML][HTML] Comparative of in-vitro evaluation between erlotinib loaded nanostructured lipid carriers and liposomes against A549 lung cancer cell line
FA Gaballu, S Abbaspour-Ravasjani… - Iranian journal of …, 2019 - ncbi.nlm.nih.gov
… Erlotinib (ELT) as a small molecule with poor solubility, poor … In the present study, ELT-liposome
and ELT-NLCs were … The obtained data from this study clearly showed that ELT-NLCs …
and ELT-NLCs were … The obtained data from this study clearly showed that ELT-NLCs …
[HTML][HTML] The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non …
HA Jung, SY Woo, SH Lee, JS Ahn… - Translational Lung …, 2020 - ncbi.nlm.nih.gov
… Study subjects and data collection This study included 599 patients with EGFR-mutant
NSCLC who started first-line gefitinib, erlotinib, afatinib treatment for advanced NSCLC at …
NSCLC who started first-line gefitinib, erlotinib, afatinib treatment for advanced NSCLC at …
Development of erlotinib-loaded nanotransferosomal gel for the topical treatment of ductal carcinoma in situ
… Aims: This study was aimed to formulate erlotinib (ERL)-loaded transferosomal gel (ERL@TG)
intended for topical application for the treatment of ductal carcinoma in situ. Materials & …
intended for topical application for the treatment of ductal carcinoma in situ. Materials & …
[HTML][HTML] Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor …
S Park, SY Lee, D Kim, YS Sim, JS Ryu, J Choi, SH Lee… - BMC cancer, 2021 - Springer
… We investigated the clinical outcomes of afatinib, erlotinib, and gefitinib according to EGFR
… is uncertain, as comparative studies have been scarce. The present study demonstrated that …
… is uncertain, as comparative studies have been scarce. The present study demonstrated that …
Antioxidant activity of erlotinib and gefitinib: theoretical and experimental insights
SH K. P, TD Babu, P C. M, G Joshy… - Free Radical …, 2022 - Taylor & Francis
… Antioxidant properties of plant extracts: an EPR and DFT comparative study of the
reaction with DPPH, TEMPOL and spin trap DMPO. J Braz Chem Soc. 2009;20(8):1483–1492. …
reaction with DPPH, TEMPOL and spin trap DMPO. J Braz Chem Soc. 2009;20(8):1483–1492. …
A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer
CTT Nguyen, F Petrelli, S Scuri, BT Nguyen… - The European Journal of …, 2019 - Springer
… After converting the currencies used in the studies to I$, using the CPI and PPP, we found
that erlotinib in the first-line treatment of advanced NSCLC had incremental cost-effectiveness …
that erlotinib in the first-line treatment of advanced NSCLC had incremental cost-effectiveness …
[HTML][HTML] Colorectal cancer growth retardation through induction of apoptosis, using an optimized synergistic cocktail of axitinib, erlotinib, and dasatinib
RH Berndsen, N Swier, JR van Beijnum… - Cancers, 2019 - mdpi.com
… ), erlotinib (20 μM), and dasatinib (0.2 μM) [20]. In this study, the activity of axitinib, erlotinib,
and … Exposure of CRC cells to 2- and 3-drug combinations of axitinib, erlotinib, and dasatinib …
and … Exposure of CRC cells to 2- and 3-drug combinations of axitinib, erlotinib, and dasatinib …